Heron Therapeutics Unternehmenskultur

Ms. Kimberly J. Manhard has been an Executive Vice President of Drug Development at Heron Therapeutics, Inc. since January 28, 2016. Ms. Manhard has been a Senior Vice President of Regulatory Affairs and Development Operations at Ardea Biosciences, Inc., since December 21, 2006. and served as its Senior Vice President of Regulatory Affairs and Operations. She has been President of her own consultancy since 2003, specializing in the development of small molecules intended for antiviral, oncology, central nervous system and gastrointestinal indications and is responsible for filing five initial US INDs and multiple clinical trial applications in the European Union and Canada. She served as Vice President of Regulatory Affairs of Napo Pharmaceuticals, Inc. She served as Senior Vice President of Regulatory Affairs & Operations of Intrabiotics Pharmaceuticals Inc. since December 22, 2006. She joined Napo Pharmaceuticals, Inc. from Exelixis, Inc., where she served as Vice President of Regulatory Affairs. She joined Agouron in 1996 as Director of Regulatory Affairs and was responsible for anticancer and antiviral products, including nelfinavir. Prior to that, she was with Agouron Pharmaceuticals, Inc. where she was responsible for global regulatory functions. She has more than 20 years of experience in the pharmaceutical industry and has participated in more than 15 IND submissions and at least six drug approvals for both small molecule and biological drugs primarily in the areas of antivirals and cancer. Her prior pharmaceuticals company experience includes Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb and Eli Lilly & Co. She served as a Director of Heron Therapeutics, Inc. since January 13, 2014 until January 28, 2016. She studied B.S. Degree in Zoology and B.A. in French from the University of Florida, Gainesville.